Shots For Six-Year-Olds – Where’s The Safety Data?

Healthcare worker giving an intramuscular injection in upper arm — Photo: Tong_stocker / Shutterstock

Drugmakers are pushing powerful weight-loss shots for children as young as six, while long-term safety in growing kids remains unknown.

Story Snapshot

Phase 3 trial found semaglutide lowered body mass index in children ages 6 to under 12.
Forty percent of treated kids moved below the obesity threshold after 68 weeks, none on placebo did.
Experts warn long-term effects on growth and development are uncharted and need caution.
Drugs are not approved for obesity in children under 12, yet off-label use is rising.

What The New Trial Shows For Kids Ages 6 To 11

Novo Nordisk reported results from STEP Young, a phase 3 trial of semaglutide in children ages 6 to under 12 with obesity. The company said the study met its main goal, showing greater body mass index reduction versus placebo. It also said 40.4 percent of treated children dropped below the obesity threshold after 68 weeks, while none on placebo did. The trial enrolled 165 children and paired the drug with diet and activity changes, which mirrors how many clinics treat obesity.

Reuters reported the same topline figure, underscoring the size of the effect in this age group. Early studies of a similar drug, liraglutide, also showed body mass index drops in children 6 to 12, which adds to the signal that these medicines can help with weight in the short term. For families facing severe obesity and related health risks, these numbers feel like hope. But numbers from one year do not answer what happens over several years of growth.

Why Doctors Urge Caution For Growing Children

Peer-reviewed reviews say most pediatric trials of glucagon-like peptide-1 medicines have been brief, usually one to two years. The authors conclude that long-term safety and lasting benefits in youth are still unknown, and the “long game” in growing children is uncharted. Another clinical review states these drugs are not approved to treat obesity in children under 12 and warns there is little data on what happens after stopping them, including weight regain risk. That gap matters when treating kids who are still developing.

Doctors quoted by Medscape say these drugs may be an add-on for some severe cases but should be limited, cautious, and closely monitored in 6- to 11-year-olds. A Stanford Medicine piece notes some doctors are prescribing to younger kids off-label, but long-term outcomes and possible effects on development remain unknown. A separate paper warns that these drugs can blunt appetite and may affect growth-hormone and insulin-like growth factor balance during key growth periods, which could carry risks we do not yet see.

Off-Label Use Is Rising Fast, But Approval And Access Lag

Research shows prescribing of these drugs to 8- to 11-year-old children with obesity rose sharply since 2019, yet only a small share of eligible kids received a prescription overall. That pattern shows fast interest but limited reach and oversight. Reviews find the medicines reduce body mass index and improve some heart risk markers in the short term, but they call for longer studies to track bone health, growth, and mental health over time. Families deserve clear answers before long-term use in kids becomes routine.

Pediatric GLP-1 talk for severe childhood obesity is a different risk-benefit frame than adult trials. Growth, long-term safety, and who qualifies matter more than adult weight-loss headlines.

— PeptPedia (@PeptPedia) September 19, 2026

Parents also face practical concerns. These drugs are costly, often need insurance hurdles, and may require long use to keep weight off. If a child stops and weight returns, that can strain health, morale, and family budgets. Policymakers and schools should double down on basics that carry no such unknowns: real food in cafeterias, daily physical activity, and community sports. Federal guidelines should protect kids from fads and make sure any drug use is narrow, supervised, and time-limited when possible.

A Common-Sense Path For Parents And Policymakers

Families should ask hard questions before starting a growing child on a weekly shot. Who will monitor growth, nutrition, and mental health every few months? What is the plan if side effects appear? How long is the target course? Studies show strong short-term weight results with semaglutide, but they do not settle long-term growth and safety. Until that evidence exists, doctors should reserve these drugs for the most severe cases and pair them with strong family-based lifestyle plans.

Leaders should keep decisions close to parents and local doctors, not drug makers or distant bureaucrats. President Trump’s administration can back rigorous trials in children, demand full safety tracking, and block any move to make schools or insurers push shots as a first step. Kids need protection from one-size-fits-all health mandates. Results should guide care, but caution should guide policy. Parents, not companies or agencies, should call the shots for their kids’ health.